Therapeutic efficacy of the angiogenesis inhibitor O-(Chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) for human anaplastic thyroid carcinoma in nude mice

Experimental and Toxicologic Pathology

Volumn 49, Issue 3-4, 1997, Pages 239-247

  Hama, Yoshihisa ^a   Shimizu, Tadahiro ^a   Hosaka, Shigetoshi ^a   Sugenoya, Akira ^a   Usuda, Nobuteru ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis inhibitor; Chloroacetyl carbamol; Fumagillin; Human thyroid anaplastic carcinoma; Thyroid carcinoma; TNP 470; Transplantation

Indexed keywords

ANGIOGENESIS INHIBITOR; CISPLATIN; DOXORUBICIN; FUMAGILLOL CHLOROACETYLCARBAMATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; THYROID CARCINOMA; ULTRASTRUCTURE;

ANIMALIA; MUS MUSCULUS; POMACANTHUS MACULOSUS;

EID: 0030841623     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0940-2993(97)80020-6     Document Type: Article

References (30)

1. ALDINGER KA, SAMAAN NA, IBANEZ M, et al.: Anaplastic carcinoma of the thyroid. Cancer 1978; 41: 2267-2275.
2. FOLKMAN J, HAUDENSCHILD C: Angiogenesis in vitro. Nature 1980; 288: 551-556.
3. FOLKMAN J, KLAGSBRUN M: Angiogenic factors. Science 1987; 235: 442-447.
4. FOLKMAN J, SHING Y: Angiogenesis. J Biol Chem, 1992; 267: 10931-10934.
5. GAAL JM, HORVATH E, KOVASC K: Ultrastructure of two cases of anaplastic giant cell tumor of the human thyroid gland. Cancer, 1975; 35: 1273-1279.
6. GERAN RI, GREENBERG NH, MACDONALD MM, et al.: Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemotherapy Reports Part 3, 1972; 3: 1-103.
7. GRAHAM H, DANIEL C: Ultrastructure of an anaplastic carcinoma of the thyroid. Am J Clin Pathol 1974; 61: 690-696.
8. INGBER D, FUJITA T, KISHIMOTO S, et al.: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990; 348: 555-557.
9. JAO W, GOULD VE: Ultrastructure of anaplastic (spindle and giant cell) carcinoma of the thyroid. Cancer 1975; 35: 1280-1292.
10. KAMEI S, OKADA H, INOUE Y, et al.: And tumor effects of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. J Pharm and Exper Therap 1993; 264: 469-474.
11. KERBEL RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991; 13: 31-36.
12. KIN JH, LEEPER RD: Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination adriamycin and radiation therapy. Cancer 1983; 52: 954-957.
13. KUSAKA M, SUDO K, FUJITA T, et al.: Potent angi-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 1991; 174: 1070-1076.
14. MARUI S, ITOH F, KOZAI Y, et al.: Chemical modification of fumagillin. I. 6-O-Acyl, 6-O-Alkyl, and 6-O-(N-Substituted-carbamoyl)fumagillols. Chem Pharm Bull 1992; 40: 96-101.
15. SEHESTED M, HOU-JENSEN K: Factor VIII - related antigen as an endothelial cell marker in benign and malignant diseases. Virchows Arch (Pathl Anat) 1981; 391: 217-225.
16. SHIMAOKA K, SCHOENFELD DA, DEWYS WD, et al.: A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985; 56: 2155-2160.
17. SHIMIZU T, USUDA N, YAMANDA T, et al.: Proliferative activity of human thyroid tumors evaluated by proliferating cell nuclear antigen/cyclin immunohistochemical studies. Cancer 1993; 71: 2807-2812.
18. SHIMOSATO Y, KAMEYA T, NAGAI K, et al.: Transplantation of human tumors in nude mice. J Natl Cancer inst 1976; 56; 1251-1260.
19. TAKAMIYA Y, FRIEDLANDER RM, BREM H, et al.: Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470. J Neurosurg 1993; 78: 470-476.
20. TOHYAMA K, YOSHIDA Y, OHASHI K, et al.: Production of multiple growth factors by a newly established human thyroid carcinoma cell line. Jpn J Cancer Res 1992; 83: 153-158.
21. TOI M, YAMAMOTO Y, IMAZAWA T, et al.: Anti tumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats. International J Oncology 1993; 3: 525-528.
22. WAKE N, HRESHCHYSHYN MM, PIVER SM, et al.: Specific cytogenetic in ovarian cancer involving chromosomes 6 and 14. Cancer Res 1980; 40: 4512-4518.
23. WAKE N, SLOCUM HK, RUSTUM YM, et al.: Chromosomes and causation of human cancer and leukemia. XLIV. A method for chromosome analysis of solid tumors. Cancer Genet Cytogenet 1980, 3: 1-10.
24. WALFISH PC, ROSEN IB: Miscellaneous tumors of the thyroid. In: BRAVERMAN LE, UTIGER RD (eds.): Werner and Ingber's The Thyroid. Ed 6 Philadelphia: JB Lippincott Co 1991 pp. 1184-1196.
25. WENISCH HLC, WAGNER RH, SCHUMM-DRAEGER P, et al.: Cytostatic drug therapy in anaplastic thyroid carcinoma. World J Surg 1986; 10: 762-769.
26. YAMAOKA M, YAMAMOTO T, IKEYAMA S, et al.: Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 1993; 53: 5233-5236.
27. YAMAOKA M, YAMAMOTO T, MASAKI T, et al.: Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor o-(chloroacetyl carbomoyl) fumagillol (TNP-470; AGM-1470). Cancer Res 1993; 53: 4262-4267.
28. YANASE T, TAMURA M, FUJITA K, et al.: Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 1993; 53: 2566-2570.
29. YOSHIDA A, FUKAZAWA M, AIYOSHI Y, et al.: The biological characteristics and chemosensitivity of anaplastic thyroid carcinoma transplanted into nude mice. Jpn J Surg 1990; 20: 690-695.
30. Personal communication with Dr. KATSUICHI SUDO, Takeda Chemical Industries, Ltd., Osaka, Japan.